-
公开(公告)号：EP4324851A3
公开(公告)日：2024-05-15
申请号：EP23215003.7
申请日：2019-07-18
发明人： DILILLO, David , DELFINO, Frank , BRAY, Kevin , MEAGHER, Thomas, Craig , KIRSHNER, Jessica , SINESHCHEKOVA, Olga
IPC分类号： A61K39/00 , A61K35/17 , A61P35/02 , C07K14/725 , C07K16/28
CPC分类号： C07K16/2878 , C07K14/7051 , C12N2502/9920130101 , C12N2501/51520130101 , A61P35/02 , C07K2319/3320130101 , A61K35/00 , A61K2239/3820230501 , A61K39/4611 , A61K39/464417 , C12N5/0636 , A61K2239/4820230501 , A61K39/4631 , A61K2239/1320230501 , A61K2239/3120230501
摘要： B-cell maturation antigen (BCMA) is expressed on malignant plasma cells. The present invention provides BCMA-specific chimeric antigen receptors and cells expressing such chimeric antigen receptors. In certain embodiments, engineered cells expressing the chimeric antigen receptors of the present invention are capable of inhibiting the growth of tumors expressing BCMA. The engineered cells of the invention are useful for the treatment of diseases and disorders in which an upregulated or induced BCMA-targeted immune response is desired and/or therapeutically beneficial. For example, engineered cells expressing the BCMA-specific chimeric antigen receptors of the invention are useful for the treatment of various cancers, including multiple myeloma.
-
2.发明公开
公开(公告)号：EP4426339A1
公开(公告)日：2024-09-11
申请号：EP22826535.1
申请日：2022-11-02
申请人： CELGENE CORPORATION
IPC分类号： A61K39/00 , C07K14/725 , A61P35/00
-
公开(公告)号：EP4417623A1
公开(公告)日：2024-08-21
申请号：EP23382147.9
申请日：2023-02-15
申请人： Fundació Institut de Recerca Contra la Leucèmia Josep Carreras , Institució Catalana de Recerca I Estudis Avançats , Onechain Immunotherapeutics SL , Fundació Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol
发明人： MENÉNDEZ BUJÁN, Pablo , SÁNCHEZ MARTÍNEZ, Diego , TIRADO CABRERA, Néstor , FERNÁNDEZ FUENTES, Narciso , DÍAZ CORTÉS, Víctor Manuel
CPC分类号： C07K16/2866 , C07K2317/2420130101 , C07K2317/62220130101 , A61K39/4611 , A61K39/4622 , A61K39/4631 , A61K39/464416 , A61K2239/4820230501 , A61K2239/1320230501 , A61P35/02
摘要： The present invention provides therapeutics for the treatment of CCR9-positive cancers such as T-cell acute lymphoblastic leukemia. In particular, the present invention provides a CCR9 targeting moiety. The present invention furthermore relates to a CCR9 targeting moiety comprising a further targeting moiety, preferably a CD1a targeting moiety.
-
-
公开(公告)号：EP4402163A1
公开(公告)日：2024-07-24
申请号：EP22870995.2
申请日：2022-09-16
申请人： The Trustees of The University of Pennsylvania , The Board of Trustees of the Leland Stanford Junior University
发明人： SIURALA, Mikko , JUNE, Carl H. , GARCIA, Kenan Christopher , CASTELLI CORTÉS, Maria Sofia , YOUNG, Regina M.
IPC分类号： C07K14/715 , A61K35/17 , A61P35/00 , C07K14/71
CPC分类号： A61P35/00 , A61K38/00 , C12N15/625 , C07K16/30 , C07K2317/62220130101 , C07K2319/0320130101 , C12N2740/1304320130101 , C12N2740/1604320130101 , C12N5/0636 , C12N2501/5120130101 , C12N2501/51520130101 , C12N2501/230220130101 , C12N2510/0020130101 , C07K14/7155 , C07K14/7051 , C07K14/70517 , C07K14/70521 , C07K14/70578 , C07K2319/0220130101 , C07K2319/3320130101 , A61K2239/1320230501 , A61K39/464468 , A61K39/4631 , A61K39/4611 , A61K48/005 , A61K2239/2220230501
-
公开(公告)号：EP4402160A1
公开(公告)日：2024-07-24
申请号：EP22870992.9
申请日：2022-09-16
申请人： The Trustees of The University of Pennsylvania , The Board of Trustees of the Leland Stanford Junior University
IPC分类号： C07K14/705 , C07K16/30 , A61K35/17
CPC分类号： A61P35/00 , A61K38/00 , C12N15/625 , C07K16/30 , C07K2317/62220130101 , C07K2319/0320130101 , C12N2740/1304320130101 , C12N2740/1604320130101 , C12N5/0636 , C12N2501/5120130101 , C12N2501/51520130101 , C12N2501/230220130101 , C12N2510/0020130101 , C07K14/7155 , C07K14/7051 , C07K14/70517 , C07K14/70521 , C07K14/70578 , C07K2319/0220130101 , C07K2319/3320130101 , A61K2239/1320230501 , A61K39/464468 , A61K39/4631 , A61K39/4611 , A61K48/005 , A61K2239/2220230501
-
7.发明公开
公开(公告)号：EP4426722A1
公开(公告)日：2024-09-11
申请号：EP22891024.6
申请日：2022-11-02
发明人： MESHINCHI, Soheil , LE, Quy , RIES, Rhonda , CASTRO, Sommer
IPC分类号： C07K14/705 , A61K35/17 , A61K47/64 , A61P35/02 , C12N5/0783 , C12N5/10 , C12N15/85
CPC分类号： A61P35/02 , C07K14/7051 , C07K16/28 , A61K39/464402 , A61K39/4611 , C07K14/70521 , C12N15/62 , C07K2317/62220130101 , C07K2319/0320130101 , C07K2319/3320130101 , C07K2317/5320130101 , C07K2317/2420130101 , C12N2740/1604320130101 , C12N5/0636 , C12N2510/0020130101 , A61K39/4631 , A61K2239/1320230501 , A61K2239/1720230501 , A61K2239/4820230501 , A61K45/06 , A61K31/7034 , A61K31/704 , A61K31/475 , A61K31/167
-
公开(公告)号：EP4424326A2
公开(公告)日：2024-09-04
申请号：EP24185893.5
申请日：2016-06-10
申请人： ImmunityBio, Inc.
发明人： LEE, Tien
IPC分类号： A61K39/395
CPC分类号： C07K16/28 , C12N2510/0020130101 , A61K39/395 , C07K16/2803 , A61K2039/50520130101 , C07K2317/62220130101 , C07K2319/0320130101 , C07K2319/3020130101 , C07K2319/3320130101 , C12N5/0646 , A61P35/00 , A61K39/46 , A61K39/464429 , A61K2239/1320230501 , A61K39/4631 , A61K2239/4820230501 , A61K39/464474 , A61K2239/3820230501 , A61K39/4613 , A61K39/464412 , A61K2239/2820230501
摘要： Provided herein are NK-92 cells expressing at least one CAR and at least one Fc receptor. Also provided are methods of treatment of a patient having or suspected of having a disease that is treatable with NK-92 cells, such as cancer, comprising administering to the patient NK-92-Fc-CAR.
-
公开(公告)号：EP4370699A2
公开(公告)日：2024-05-22
申请号：EP22843094.8
申请日：2022-07-18
CPC分类号： C12N15/63 , C07K14/7051 , C12N5/0636 , C12N2510/0020130101 , C12N15/86 , C12N2740/1604320130101 , C07K14/70503 , A61K39/4611 , A61K39/4631 , A61K39/464412 , A61K39/464429 , A61K2239/1320230501 , A61K2239/2820230501 , A61K2239/2320230501 , A61K39/461 , A61K39/464413 , C07K16/2803 , A61P35/00 , A61K2039/50520130101 , A61K39/4621 , A61K39/464402 , A61K2239/3120230501 , A61K2239/2920230501 , A61K39/46434
-
-
-
-
-
-
-
-
搜索结果
9 条记录 (耗时 0.009 秒)
